WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522389
CAS#: 353262-04-1
Description: NS6180 is a potent KCa3.1 channel blocker (IC50 values are 9, 14 and 15 nM for rat, human and mouse erythrocyte KCa3.1 channels respectively). NS6180 prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. NS6180 shows ~ 50% inhibition of KCa1.1, KV1.3, and KV11.1 channels, NS6180 represents a novel class of K(Ca) 3.1 channel inhibitors which inhibited experimental colitis, suggesting K(Ca) 3.1 channels as targets for pharmacological control of intestinal inflammation.
MedKoo Cat#: 522389
Name: NS6180
CAS#: 353262-04-1
Chemical Formula: C16H12F3NOS
Exact Mass: 323.05917
Molecular Weight: 323.33
Elemental Analysis: C, 59.44; H, 3.74; F, 17.63; N, 4.33; O, 4.95; S, 9.92
NS6180, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 2g may be 2 weeks.
Synonym: NS6180; NS-6180; NS 6180.
IUPAC/Chemical Name: 4-[[3-(Trifluoromethyl)phenyl]methyl]-2H-1,4-benzothiazin-3(4H)-one
InChi Key: ZUIJXKLTUFCDGO-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H12F3NOS/c17-16(18,19)12-5-3-4-11(8-12)9-20-13-6-1-2-7-14(13)22-10-15(20)21/h1-8H,9-10H2
SMILES Code: O=C1CSC2=CC=CC=C2N1CC3=CC=CC(C(F)(F)F)=C3
The following data is based on the product molecular weight 323.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Jenkins DP, Yu W, Brown BM, Løjkner LD, Wulff H. Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators. Assay Drug Dev Technol. 2013 Nov-Dec;11(9-10):551-60. doi: 10.1089/adt.2013.543. PubMed PMID: 24351043; PubMed Central PMCID: PMC3870577.
2: Koshy S, Wu D, Hu X, Tajhya RB, Huq R, Khan FS, Pennington MW, Wulff H, Yotnda P, Beeton C. Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS One. 2013 Oct 11;8(10):e76740. doi: 10.1371/journal.pone.0076740. eCollection 2013. PubMed PMID: 24146918; PubMed Central PMCID: PMC3795664.
3: Jørgensen S, Dyhring T, Brown DT, Strøbæk D, Christophersen P, Demnitz J. A high-throughput screening campaign for detection of ca(2+)-activated k(+) channel activators and inhibitors using a fluorometric imaging plate reader-based tl(+)-influx assay. Assay Drug Dev Technol. 2013 Apr;11(3):163-72. doi: 10.1089/adt.2012.479. Epub 2012 Nov 30. PubMed PMID: 23198866.
4: Strøbæk D, Brown DT, Jenkins DP, Chen YJ, Coleman N, Ando Y, Chiu P, Jørgensen S, Demnitz J, Wulff H, Christophersen P. NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. Br J Pharmacol. 2013 Jan;168(2):432-44. doi: 10.1111/j.1476-5381.2012.02143.x. PubMed PMID: 22891655; PubMed Central PMCID: PMC3572569.
